Viemed Healthcare, Inc. (NASDAQ:VMD – Get Free Report) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 450,066 shares, an increase of 29.5% from the February 26th total of 347,585 shares. Currently, 1.5% of the company’s shares are short sold. Based on an average daily volume of 418,682 shares, the days-to-cover ratio is presently 1.1 days.
Viemed Healthcare Price Performance
VMD stock opened at $9.25 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.06 and a current ratio of 1.18. Viemed Healthcare has a 1 year low of $5.93 and a 1 year high of $10.06. The firm has a market cap of $357.05 million, a P/E ratio of 25.00 and a beta of 1.23. The stock has a 50-day simple moving average of $8.49 and a 200-day simple moving average of $7.45.
Viemed Healthcare (NASDAQ:VMD – Get Free Report) last announced its earnings results on Wednesday, March 4th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. The business had revenue of $76.18 million for the quarter, compared to the consensus estimate of $77.70 million. Viemed Healthcare had a return on equity of 10.72% and a net margin of 5.53%.
Insider Buying and Selling at Viemed Healthcare
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue acquired a new stake in Viemed Healthcare during the 4th quarter valued at $25,000. Kemnay Advisory Services Inc. acquired a new position in Viemed Healthcare in the 4th quarter worth $46,000. Quarry LP acquired a new position in Viemed Healthcare in the 3rd quarter worth $48,000. AQR Capital Management LLC purchased a new position in Viemed Healthcare in the 1st quarter valued at about $90,000. Finally, SG Americas Securities LLC purchased a new position in Viemed Healthcare in the 4th quarter valued at about $101,000. 74.24% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 14th. Zacks Research raised shares of Viemed Healthcare to a “hold” rating in a research report on Thursday, January 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Viemed Healthcare in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Viemed Healthcare currently has a consensus rating of “Hold”.
View Our Latest Analysis on VMD
About Viemed Healthcare
Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.
Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.
Featured Articles
Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
